9/24/2024

Testosterone Cypionate Injection

Products Affected - Description

- Depo-Testosterone intramuscular injection, Pfizer, 100 mg/mL, 10 mL vial, NDC 00009-0347-02
- Depo-Testosterone intramuscular injection, Pfizer, 200 mg/mL, 1 mL vial, 1 count, NDC 00009-0417-01
- Depo-Testosterone intramuscular injection, Pfizer, 200 mg/mL, 10 mL vial, 1 count, NDC 00009-0417-02
- Testosterone cypionate intramuscular injection, Eugia US, 200 mg/mL, 10 mL vial, 1 count, NDC 55150-0278-01
- Testosterone cypionate intramuscular injection, Hikma, 200 mg/mL, 1 mL vial, 1 count, NDC 00143-9659-01
- Testosterone cypionate intramuscular injection, Hikma, 200 mg/mL, 10 mL vial, 1 count, NDC 00143-9726-01
- Testosterone cypionate intramuscular injection, Padagis, 200 mg/mL, 1 mL vial, 1 count, NDC 00574-0820-01
- Testosterone cypionate intramuscular injection, Padagis, 200 mg/mL, 10 mL vial, 1 count, NDC 00574-0820-10
- Testosterone cypionate intramuscular injection, Pfizer, 100 mg/mL, 10 mL vial, 1 count, NDC 00409-6557-01
- Testosterone cypionate intramuscular injection, Pfizer, 200 mg/mL, 1 mL vial, 1 count, NDC 00409-6562-01
- Testosterone cypionate intramuscular injection, Pfizer, 200 mg/mL, 10 mL vial, 1 count, NDC 00409-6562-20
- Testosterone cypionate intramuscular injection, Sun Pharma, 100 mg/mL, 10 mL vial, 1 count, NDC 62756-0017-40 - discontinued
- Testosterone cypionate intramuscular injection, Sun Pharma, 200 mg/mL, 1 mL vial, 1 count, NDC 62756-0015-40 - discontinued
- Testosterone cypionate intramuscular injection, Sun Pharma, 200 mg/mL, 10 mL vial, 1 count, NDC 62756-0016-40 - discontinued

Reason for the Shortage

- Cipla did not provide a reason for the shortage. The 200 mg/mL 10 mL vials were discontinued in 2022.
- Eugia launched testosterone cypionate in late-2023.
- Hikma did not provide a reason for the shortage.
- Padagis did not provide a reason for the shortage. They are focusing on the 1 mL size.
- Pfizer has testosterone cypionate and Depo-Testosterone on shortage due to increased demand and manufacturing delays.
- Sun Pharma discontinued testosterone cypionate in late-2023.

Available Products

- Testosterone cypionate intramuscular injection, Cipla USA, 200 mg/mL, 1 mL vial, 1 count, NDC 69097-0802-32
- Testosterone cypionate intramuscular injection, Eugia US, 100 mg/mL, 10 mL vial, 1 count, NDC 55150-0276-01
- Testosterone cypionate intramuscular injection, Eugia US, 200 mg/mL, 1 mL vial, 1 count, NDC 55150-0277-01

Estimated Resupply Dates

- Eugia has testosterone cypionate 200 mg/mL 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Hikma has testosterone cypionate 200 mg/mL 1 mL and 10 mL vials on allocation.
- Padagis has testosterone cypionate 200 mg/mL 1 mL vials on allocation. The 10 mL vials are on long-term back order and the company cannot estimate a release date.
- Pfizer has testosterone cypionate 200 mg/mL 1 mL and 10 mL vials and 100 mg/mL 10 mL vials available in limited supply.
- Pfizer has Depo-Testosterone 100 mg/mL 10 mL vials on back order and the company estimates a release date of November 2024. The 200 mg/mL 1 mL and 10 mL vials are on back order and the company estimates a release date of December 2027.

Updated

Updated September 24, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 11, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.